Y-mAbs Therapeutics, Inc. announced the appointment of Norman LaFrance, M.D. as chief development officer. Dr. LaFrance brings over 40 years of deep radiopharmaceutical experience as both a nuclear medicine physician and pharmaceutical executive. He previously served as the Chief Medical Officer, Senior Vice President of PLUS Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company where he led the development of targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers.

Before Plus Therapeutics, Dr. LaFrance served as Chief Medical Officer at Jubilant Pharma Ltd., where he was responsible for all Pharmaceutical & Medical Regulatory Affairs activities. Prior to Jubilant, Dr. LaFrance served as Global Chief Medical Officer at IBA Molecular and earlier, as Senior Vice President and Chief Medical Officer of Molecular Insight Pharmaceuticals, Inc. Dr. LaFrance practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the departments of Medicine and Radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is Double Board Certified with Fellowship status both in internal medicine and nuclear medicine, maintains active medical licensure in the U.S. along with active, professional society membership.

Dr. LaFrance received his B.S and Master of Engineering degrees in nuclear engineering and science from Rensselaer Polytechnic Institute, and his M.D. from the University of Arizona, College of Medicine, Tucson.